Ratings MedPlus Health Services Limited

Equities

MEDPLUS

INE804L01022

Delayed NSE India S.E. Other stock markets 11:28:24 17/05/2024 am IST			5-day change	1st Jan Change
698.6 ^INR	-0.80%		-0.69%	-6.95%

05/05	Optival Health Solutions Private Limited Received Order for Temporarily Suspending the Operations of Store situated at Prakash Nagar Kurnool District Andra Pradesh, C.B Pura Road and MB Road Kolar, Karnataka for seven days each store	CI
25/03	Medplus Health Services Arm Gets Order for Temporary Suspension of Operations	MT

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 161.77 times its estimated earnings per share for the ongoing year.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Ratings chart - Surperformance

Sector: Drug Retailers

	1st Jan change	Capi.	ESG Refinitiv
MEDPLUS HEALTH SERVICES LIMITED	-6.95%	1.01B	-
WALGREENS BOOTS ALLIANCE, INC.	-29.72%	15.82B	B-
JD HEALTH INTERNATIONAL INC.	-22.89%	12.65B	B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-23.82%	6.6B	B
YIFENG PHARMACY CHAIN CO., LTD.	+12.34%	6.3B	C
MATSUKIYOCOCOKARA & CO.	-6.13%	6.11B	C+
NAHDI MEDICAL COMPANY	-1.17%	4.69B	D-
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+64.02%	4.75B	C
CLICKS GROUP LIMITED	-5.50%	4.02B	B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-8.59%	3.59B	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes